# A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

> **NCT05210868** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 184 (estimated)

## Conditions studied

- Hematoma

## Interventions

- **DRUG:** CM355

## Key facts

- **NCT ID:** NCT05210868
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-16
- **Primary completion:** 2026-12-28
- **Final completion:** 2026-12-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210868, "A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05210868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*